Legal Representation
Attorney
Nicole E. Reifman
USPTO Deadlines
Application History
49 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Aug 8, 2025 | RDX1 | O | ACTION FOR REQ FOR RECON DENIED NO APPEAL FILED E-MAILED | Loading... |
| Aug 8, 2025 | RDX3 | O | NOTIFICATION FOR REQ FOR RECON DENIED NO APPEAL FILED | Loading... |
| Aug 8, 2025 | RRDX | W | ACTION REQ FOR RECON DENIED NO APPEAL FILED COUNTED NOT MAILED | Loading... |
| Aug 7, 2025 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Aug 7, 2025 | ERFR | I | TEAS REQUEST FOR RECONSIDERATION RECEIVED | Loading... |
| Aug 7, 2025 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| May 7, 2025 | XELG | O | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | Loading... |
| May 7, 2025 | XELR | I | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | Loading... |
| Feb 7, 2025 | CNFR | W | SU - FINAL REFUSAL - WRITTEN | Loading... |
| Feb 7, 2025 | GNFR | O | FINAL REFUSAL E-MAILED | Loading... |
| Feb 7, 2025 | GNFN | O | NOTIFICATION OF FINAL REFUSAL EMAILED | Loading... |
| Dec 10, 2024 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Dec 10, 2024 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Dec 10, 2024 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Nov 4, 2024 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Sep 13, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Aug 2, 2024 | XELR | I | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | Loading... |
| Aug 2, 2024 | XELG | O | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | Loading... |
| May 4, 2024 | CNRT | W | SU - NON-FINAL ACTION - WRITTEN | Loading... |
| May 4, 2024 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| May 4, 2024 | GNRT | O | NON-FINAL ACTION E-MAILED | Loading... |
| Apr 4, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Apr 3, 2024 | SUPC | I | STATEMENT OF USE PROCESSING COMPLETE | Loading... |
| Apr 3, 2024 | EX3G | S | SOU EXTENSION 3 GRANTED | Loading... |
| Apr 3, 2024 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
| Mar 13, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Mar 13, 2024 | IUAF | S | USE AMENDMENT FILED | Loading... |
| Mar 13, 2024 | EXT3 | S | SOU EXTENSION 3 FILED | Loading... |
| Mar 13, 2024 | EISU | I | TEAS STATEMENT OF USE RECEIVED | Loading... |
| Sep 15, 2023 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Sep 13, 2023 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| Sep 13, 2023 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| Sep 13, 2023 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Mar 8, 2023 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Mar 6, 2023 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Mar 6, 2023 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Mar 6, 2023 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Sep 13, 2022 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Jul 19, 2022 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Jul 19, 2022 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Jun 29, 2022 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Jun 10, 2022 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Jun 10, 2022 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
| Jun 10, 2022 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
| Jun 10, 2022 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
| Jun 10, 2022 | GNEA | F | EXAMINERS AMENDMENT E-MAILED | Loading... |
| Jun 2, 2022 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Oct 29, 2021 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Oct 7, 2021 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 001
Chemicals used in the manufacture of pharmaceuticals; biomedical compounds, namely, recombinant and synthetic polypeptides for universal masking of proteins and providing half-life extension, and protease-cleavable linkers to enable unmasking
First Use Anywhere:
20230100
First Use in Commerce:
20230100
Class 005
Pharmaceutical preparations for the treatment of cancerous and viral diseases; pharmaceutical preparations for use in the field of oncology for the treatment of cancerous diseases; medical diagnostic reagents
First Use Anywhere:
20230100
First Use in Commerce:
20230100
Classification
International Classes
001
005